Compare ATYR & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | OFS |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | 58 | 47 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.1M | 54.3M |
| IPO Year | N/A | N/A |
| Metric | ATYR | OFS |
|---|---|---|
| Price | $0.54 | $3.34 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $3.67 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 80.8K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 16.83% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $2.72 |
| 52 Week High | $7.29 | $8.99 |
| Indicator | ATYR | OFS |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 42.47 |
| Support Level | $0.42 | $3.31 |
| Resistance Level | $0.59 | $4.40 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 75.87 | 11.24 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.